Abstract Number: PB2440
Meeting: ISTH 2020 Congress
Theme: Venous Thromboembolism and Cardioembolism » VTE Treatment
Background: Direct oral anticoagulants (AOD) have known great success since their arrival on the market more than 10 years ago. Unlike Vitamin K antagonist (VKA), their use does not require regular monitoring of INR, however they are not without risks.
Aims: The objective of our survey is to establish an inventory on the prescription of AOD in Algeria. Our study aims to assess the use of AOD and to understand the possible obstacles to their prescription.
Methods: We carried out a declarative cross-sectional study with a sample of liberal and hospital specialists selected randomly, during the period from January to April 2019. The questionnaire included 29 questions divided into 3 items: professional characteristics, prescription of AOD and biological monitoring.
Results: According to the results of our study, the prescription of AODs is modest compared to the VKA which remain the most prescribed in Algeria.
The major obstacle that holds prescription in Algeria is firstly the unavailability of all AODs on the market, only rivaroxaban is marketed. Besides these economic brakes, the risk of hemorrhage, the lack of biological monitoring of the anticoagulant activity which makes it possible to appreciate the tolerance and the harmlessness of these molecules as well as the absence of antidote constitute the main factors influencing the therapeutic decision of our doctors in terms of approval and prescription of AOD. Regarding the evaluation of anticoagulant activity by measuring anti-FIIa and anti-Xa activity, our study has shown that all doctors want to have it available in analysis laboratories.
Conclusions: Faced with the multiplication of anticoagulants, and their own operating mode, it becomes complicated for prescribers to find their way around but over time, new anticoagulants will certainly find their place. The availability of specific anticoagulation assessment tests and the marketing of antidotes should reassure them and strengthen their use in everyday practice.
To cite this abstract in AMA style:
Bounaas S. Survey on the Prescription and Biological Monitoring of Direct Oral Anticoagulants in Algeria [abstract]. Res Pract Thromb Haemost. 2020; 4 (Suppl 1). https://abstracts.isth.org/abstract/survey-on-the-prescription-and-biological-monitoring-of-direct-oral-anticoagulants-in-algeria/. Accessed October 2, 2023.« Back to ISTH 2020 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/survey-on-the-prescription-and-biological-monitoring-of-direct-oral-anticoagulants-in-algeria/